Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Béné, Marie C  [Clear All Filters]
2024
Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, et al. Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide. Am J Hematol. 2024.
2023
Le Bourgeois A, Jullien M, Garnier A, Peterlin P, Béné MC, Guillaume T, Chevallier P. Post-transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced-intensity conditioning allotransplant. Clin Transl Med. 2023;13(4):e1242.
2022
Letailleur V, Le Bourgeois A, Guillaume T, Jullien M, Coste-Burel M, Béné MC, Chevallier P. Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France. JAMA Netw Open. 2022;5(12):e2247534.
Jullien M, Le Bourgeois A, Coste-Burel M, Peterlin P, Garnier A, Rimbert M, Imbert B-M, Le Gouill S, Moreau P, Mahe B, et al. B-cell aplasia is the most powerful predictive marker for poor humoral response after BNT162b2 mRNA SARS-CoV-2 vaccines in recipients of allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2022.
Chevallier P, Jullien M, Peterlin P, Garnier A, Le Bourgeois A, Coste-Burel M, Béné MC, Guillaume T. Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients. Hematol Oncol. 2022.
Porwit A, Violidaki D, Axler O, Lacombe F, Ehinger M, Béné MC. Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic Flow-Self Organizing Maps algorithm. Cytometry B Clin Cytom. 2022.
2020
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert B-M, Daguindau E, Mahe B, Dubruille V, Blin N, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2020:1-9.
Nehme A, Dakik H, Picou F, Cheok M, Preudhomme C, Dombret H, Lambert J, Gyan E, Pigneux A, Recher C, et al. Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. Blood Adv. 2020;4(20):5322-5335.
Vignon C, Lachot S, Foucault A, Ravalet N, Gyan E, Picou F, Herault B, Le Nail L-R, Béné MC, Herault O. Reactive oxygen species levels differentiate CD34 human progenitors based on CD38 expression. Cytometry B Clin Cytom. 2020.
2019
Picou F, Vignon C, Debeissat C, Lachot S, Kosmider O, Gallay N, Foucault A, Estienne M-H, Ravalet N, Béné MC, et al. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv. 2019;3(24):4271-4279.
Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, et al. Influence of donor type (sibling vs matched-unrelated donor vs haplo-identical donor) on outcomes after clofarabine-based reduced-intensity conditioning allograft for myeloid malignancies. Biol Blood Marrow Transplant. 2019.
2018
Bouard L, Bodet-Milin C, Bailly C, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, et al. A 4 or 5 Deauville score assessed by (18)F-FDG-PET CT early post-allotransplant is highly predictive of relapse in lymphoma patients. Biol Blood Marrow Transplant. 2018.
Raimbault A, Machherndl-Spandl S, Itzykson R, Clauser S, Chapuis N, Mathis S, Lauf J, Alary A-S, Burroni B, Kosmider O, et al. CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. Br J Haematol. 2018.